Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The clinical pharmacology of 5-trifluoromethyl-2'-deoxyuridine.

× No keyword cloud information.

18 in total

Review 1. Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors: L A Pagliaro; L Z Benet
Journal: J Pharmacokinet Biopharm Date: 1975-10

Review 2. TAS-102, a novel antitumor agent: a review of the mechanism of action.

Authors: Heinz-Josef Lenz; Sebastian Stintzing; Fotios Loupakis
Journal: Cancer Treat Rev Date: 2015-06-06 Impact factor: 12.111

3. Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry.

Authors: James J Lee; Jabed Seraj; Kenichiro Yoshida; Hirokazu Mizuguchi; Sandra Strychor; Jillian Fiejdasz; Tyeler Faulkner; Robert A Parise; Patrick Fawcett; Laura Pollice; Scott Mason; Jeremy Hague; Marie Croft; James Nugteren; Charles Tedder; Weijing Sun; Edward Chu; Jan Hendrik Beumer
Journal: Cancer Chemother Pharmacol Date: 2016-01-19 Impact factor: 3.333

4. Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks.

Authors: Norihiko Suzuki; Fumio Nakagawa; Mamoru Nukatsuka; Masakazu Fukushima
Journal: Exp Ther Med Date: 2011-03-21 Impact factor: 2.447

5. Trifluoromethylation of arenes and heteroarenes by means of photoredox catalysis.

Authors: David A Nagib; David W C MacMillan
Journal: Nature Date: 2011-12-08 Impact factor: 49.962

Review 6. TAS-102: a novel antimetabolite for the 21st century.

Authors: Nataliya Uboha; Howard S Hochster
Journal: Future Oncol Date: 2015-11-30 Impact factor: 3.404

7. Inhibition of human cytomegalovirus by trifluorothymidine.

Authors: S A Spector; M Tyndall; E Kelley
Journal: Antimicrob Agents Chemother Date: 1983-01 Impact factor: 5.191

8. Antitumor activity of FTC-092, a masked 5-trifluoromethyl-2'-deoxyuridine derivative.

Authors: S Takeda; J Yamashita; H Saito; J Uchida; H Satake; Y Yamada; N Unemi; Y Wataya; H Hayatsu
Journal: Cancer Chemother Pharmacol Date: 1991 Impact factor: 3.333

9. Activity of trifluorothymidine against cytomegalovirus.

Authors: J R Wingard; R K Stuart; R Saral; W H Burns
Journal: Antimicrob Agents Chemother Date: 1981-09 Impact factor: 5.191

10. Potentiation of the antitumor activity of 5-trifluoromethyl-2'-deoxyuridine by the use of depot forms of the parent compound.

Authors: S Takeda; K Wierzba; J Yamashita; H Matsumoto; H Satake; Y Yamada; N Unemi; Y Wataya; H Hayatsu
Journal: Cancer Chemother Pharmacol Date: 1992 Impact factor: 3.333